Abstract:Background: Neoadjuvant chemotherapy in patients with primary osteosarcoma improves survival rates, but it also causes side effects in various organs including bone. Low bone mineral density (BMD) can occur owing partly to chemotherapy or limited mobility. This can cause a higher risk of fractures compared with those who do not receive such treatment. Changes in BMD alone cannot explain the propensity of fractures. Studying microarchitectural changes of bone might help to understand the effect. Questions/purposes: (1) Do patients who were treated for osteosarcoma (more than 20 years previously) have low BMD? (2) Do these patients experience more fractures than controls who do not have osteosarcoma? (3) What differences in bone microarchitecture are present between patients treated for high-grade osteosarcoma and individuals who have never had osteosarcoma? Methods: We contacted 48 patients who were treated for osteosarcoma and who participated in an earlier study. These patients underwent multimodal treatment including chemotherapy more than 20 years ago. Of the original patient group, 60% (29 of 48) were missing, leaving 40% (19 of 48) available for inclusion in this study; all 19 agreed to participate. There were nine men and 10 women with a mean age of 46 ± 4 years and a mean time from surgery to examination of 28 ± 3 years. BMD was measured by dual-energy x-ray absorptiometry, and any fracture history was assessed using a questionnaire. Additionally, high-resolution peripheral quantitative CT was performed to compare the groups in terms of microarchitectural changes, such as cortical and trabecular area, cortical and trabecular thickness, cortical porosity, and endocortical perimeter. Participants in the control group were selected from a cohort consisting of a population-based random sample of 499 healthy adult women and men. Osteoporosis or low BMD was not an exclusion criterion for entering this study; however, the patients in the control group were selected based on a normal BMD (that is, T score > -1.0 at both the spine and hip). Also, the participants were matched based on age and sex. Differences between patients and controls were assessed using the Wilcoxon rank sum test for continuous variables and a chi-square test for categorical variables. A multiple regression analysis was performed. Model assumptions were checked using histograms and quantile-quantile plots of residuals. Results: Twelve of 19 patients who were treated for osteosarcoma had either osteopenia (eight patients) or osteoporosis (four patients). More patients with osteosarcoma reported sustaining fractures (11 of 19 patients) than did control patients (2 of 19 controls; p < 0.001). Among all microarchitectural parameters, only the endocortical perimeter was increased in patients compared with the control group (75 ± 15 mm versus 62 ± 18 mm; p = 0.04); we found no differences between the groups in terms of cortical and trabecular area, cortical and trabecular thickness, or cortical porosity. Conclusion: Although patients who were treated for osteosarcoma had osteopenic or osteoporotic BMD and a higher proportion of patients experienced fractures than did patients in the control group, we could not confirm differences in microarchitectural parameters using high-resolution peripheral quantitative CT. Therefore, it seems that bone geometry and microstructural parameters are not likely the cause of the increased proportion of fractures observed in our patients who were treated for osteosarcoma. Until we learn more about the bone changes associated with chemotherapy in patients with osteosarcoma, we recommend that patients undergo regular BMD testing, and we recommend that physicians consider osteoporosis treatment in patients with low BMD. These data might provide the impetus for future multicenter prospective studies examining the association between chemotherapy and bone microarchitecture. Level of evidence: Level III, therapeutic study.

Burden of comorbidities: Osteoporotic vertebral fracture during non-small cell lung cancer - the BONE study

Association between osteoporosis and bone metastasis of lung cancer based on opportunistic screening by low-dose computer tomography: a retrospective cohort study

Risk Factors and Prognosis Value of Venous Thromboembolism in Patients with Advanced Non-Small Cell Lung Cancer: a Case-Control Study

Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors

Quantifying the Impact of Comorbidities on Outcomes Following Surgery for Osteoporotic Vertebral Compression Fractures

Real World Clinical Outcomes When Discontinuing Denosumab or Bisphosphonates in Patients with Surgically Managed Osteoporotic Vertebral Compression Fractures: A Population-Based Cohort Study

Impact of Bone-Targeted Treatments on Skeletal Morbidity and Survival in Breast Cancer

Anti-osteoporosis drugs reduce mortality in cancer patients: A national cohort study of elderly with vertebral fractures

Retrospective Study of EGFR‐mutant Lung Adenocarcinoma with Bone Metastatic Clinical Features

Is There an Association Between Bone Microarchitecture and Fracture in Patients who were Treated for High-grade Osteosarcoma? A Controlled Study at Long-term Follow-up Using High-resolution Peripheral Quantitative CT

Bone Metastases, Skeletal-Related Events, And Survival In Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

Osteoporosis is Associated with Increased Minor Complications Following Single Level ALIF and PSIF: an Analysis of 7,004 Patients.

Osteoporosis after adjuvant treatment for early-stage breast cancer

Correlation study between osteoporosis and hematopoiesis in the context of adjuvant chemotherapy for breast cancer

Impact of bone metastasis on prognosis in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

Predictive Significance of Bone Sialoprotein and Osteopontin for Bone Metastases in Respectable Non-Small Cell Lung Cancer: A Retrospective Study

Prognostic significance of bone markers in patients with lung cancer metastatic to the skeleton: a review of published data.

Effectiveness of immune checkpoint inhibitor therapy on bone metastases in non-small-cell lung cancer

Predictive Significance Of Bone Sialoprotein And Osteopontin For Bone Metastases In Resected Chinese Non-Small-Cell Lung Cancer Patients: A Large Cohort Retrospective Study

Independent predictors of vertebral compression fracture following radiation for metastatic spine disease

Fat Body Mass and Vertebral Fracture Progression in Women With Breast Cancer